Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882877 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
A Phase 3 study of Atopic Dermatitis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 2,621
- Enrollment target
- 20
- Study locations
NCT05882877 is a Phase 3 study of Atopic Dermatitis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 2,621 participants, above the 592-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (343% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05882877, a Phase 3 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,621 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rocatinlimab
Study Locations (20)
California
- Kern Research Inc - Bakersfield
- Hope Clinical Research LLC - Canoga Park
- West Coast Research LLC - Dublin
- California Dermatology and Clinical Research Institute - Encinitas
- First OC Dermatology - Fountain Valley
- Antelope Valley Clinical Trials - Lancaster
- Chemidox Clinical Trials Incorporated - Lancaster
- Long Beach Research Institute - Long Beach
- University of California Los Angeles - Los Angeles
- Dermatology Research Associates - Los Angeles
- Wallace Medical Group Inc - Los Angeles
- Northridge Clinical Trials - Northridge
Arizona
- Medical Dermatology Specialists - Phoenix
- Alliance Dermatology and Mohs Center - Phoenix
- Affiliated Dermatology - Scottsdale
- Scottsdale Clinical Trials - Scottsdale
Arkansas
- Dermatology Trial Associates - Bryant
- Burke Pharmaceutical Research - Hot Springs
- Arkansas Research Trials, LLC - North Little Rock
Alabama
- Cahaba Dermatology and Skin Health Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,621 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05882877
The ClinicalTrials.gov registry entry for NCT05882877 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,621 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 592-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (343% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05882877 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05882877 about?
NCT05882877 is a clinical study titled "A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)". The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
What is the current status of trial NCT05882877?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,621 participants. The study started on 2023-05-31. Estimated completion is 2027-06-30.
What conditions does trial NCT05882877 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05882877?
The interventions under investigation include: Placebo (OTHER), Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT05882877?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05882877 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.